Related Experiment Video
Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer
1University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Abstract:
Androgens play a key role in prostate cancer (PCa) development and progression. For decades, androgen deprivation therapy (ADT) has been the primary treatment for men with metastatic prostate cancer. ADT initially results in the regression of prostate cancers, however, this effect is limited and patients inevitably develop an androgen refractory form of the disease. Many studies have implicated the androgen receptor (AR), the key mediator of androgen action, as an important player in PCa recurrence. Changes such as AR gene amplification, AR mutations, and in AR subcellular localization, and AR coregulator status that result in the upregulation of AR activity are often associated with androgen refractory prostate cancers. This review seeks to highlight some of the changes in the AR axis in androgen refractory tumors and the recent advances in ADT. A greater understanding of the AR axis will provide a basis for improving existing methods and developing new methods for the treatment of prostate cancer.
Insights
Androgen deprivation therapy (ADT) is a primary prostate cancer (PCa) treatment, but resistance develops. This review explores changes in the androgen receptor (AR) axis driving treatment resistance and advances in ADT.
Area of Science:
- Oncology
- Urology
- Molecular Biology
Background:
- Androgens are crucial in prostate cancer (PCa) development and progression.
- Androgen deprivation therapy (ADT) is the standard treatment for metastatic PCa.
- Prostate tumors often become resistant to ADT, leading to disease recurrence.
Purpose of the Study:
- To review alterations in the androgen receptor (AR) signaling axis in treatment-resistant prostate cancer.
- To highlight recent advancements in androgen deprivation therapy for prostate cancer.
Main Methods:
- Literature review of studies on androgen receptor function in prostate cancer.
- Analysis of molecular changes associated with treatment resistance.
- Examination of emerging therapeutic strategies for advanced prostate cancer.
Main Results:
- AR gene amplification, mutations, and altered localization contribute to treatment resistance.
- Upregulation of AR activity is a common mechanism in refractory prostate cancers.
- Recent advances in ADT offer new therapeutic avenues.
Conclusions:
- Understanding AR axis changes is vital for overcoming treatment resistance in PCa.
- Targeting the AR pathway holds promise for improved prostate cancer therapies.
- Further research into AR biology will guide the development of novel treatment strategies.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Abnormal Proliferation
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Testosterone: Functions and Regulation